NCT04175925View on ClinicalTrials.gov

A Study Assessing the Drug Levels, Drug Effects, and Safety of BMS-986322 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

171

Participants

Timeline

Start Date

November 15, 2019

Primary Completion Date

July 13, 2021

Study Completion Date

July 13, 2021

Conditions
Healthy Participants
Interventions
DRUG

BMS-986322

Specified Dose on Specified Days

OTHER

BMS-986322 Placebo

Specified Dose on Specified Days

DRUG

famotidine

Specified Dose on Specified Days

Trial Locations (1)

66219

ICON (LPRA) - Lenexa, Lenexa

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY